Nice Quality Standards for IBD
Friday, 27 February 2015 10:42
Professor Chris Probert, Chair BSG IBD Section Committee
"The BSG welcomes the release of Quality Standards for IBD by NICE. The four statements are necessarily succinct and members should read the more detailed version on the NICE website. This document sets a standard that should be recognised by CCGs and Trusts and should enable us to raise the quality of our services. These standards should form the basis of the forthcoming IBD Accreditation, along with the IBD Audit and Registry."
Changes in HCV therapy - approval of Sofosbuvir
Friday, 30 January 2015 13:55
Dr Stephen Ryder, BSG Vice-President Hepatology & Dr Andrew Austin, Chair BSG Liver Section
There are two major changes in HCV therapy which now have NICE and/or NHSE approval for use. The first is that commissioning guidance for the use of Simiprevir is published (http://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-a/a02/). This allows G1 patients without Q80K to access triple therapy now using Simiprevir instead of Boceprevir or Telaprevir.
The second and probably more significant development is the approval of Sofosbuvir. The approval can be summarised as below:
Sofosbuvir in combination with pegylated interferon + ribavirin (Peg-IFN+RBV)
|HCV genotype||Adult patient population|
|Genotype 3||Treatment-naïve with cirrhosisa|
|Genotype 4, 5, or 6||Treatment-naïve & experienced with cirrhosisa|
Sofosbuvir in combination with RBV
|HCV genotype||Adult patient population|
|Genotype 3||Treatment-naïve with cirrhosisb|
|Treatment-experienced with cirrhosisb|
The NHSE approval is for cirrhotic patients to access treatment in April with non-cirrhotic patients from July.
There is a meeting at Barts on 3rd March 2015 (advertised by BVHG) to establish clinical guidelines as to who to treat with what when. It is highly likely that by July other agents approvals will make the interferon component of the regimen outdated. NHSE will establish a process by which the drugs will be distributed shortly but it would seem prudent for centres to enter local negotiations now in order all are ready to prescribe when we are given the approvals. It is pretty certain that similar data gathering will be required as for EAP.
SAGE Awards, a national awards programme to recognise excellence in gastroenterology, is now accepting entries for 2015
Friday, 09 January 2015 09:58
The SAGE Awards - Shire Awards for Gastrointestinal Excellence, is now accepting entries for the 2015 Awards. This is the 5th year of the awards, which are supported by Shire and are designed to allow individual healthcare professionals, units and healthcare networks in gastrointestinal (GI) care to be recognised for innovative work, share best practice and raise standards of patient care. Three awards will be made in the form of financial grants to the amount of £10,000, £5,000 and £3,000, for use towards furthering the development of the winning projects. In 2014 the winning team was Dr Matthew Johnson's team at Luton & Dunstable for their IBD self-help programme.
Applications must be consultant led and will be accepted from all professional groups working in GI care, including patient representative groups working in collaboration with clinical teams. Collaborative projects bringing together professionals from two or more health board areas or across specialities, disciplines or sectors are also welcomed.
The awards judging panel will oversee the evaluation, assessment and awarding of the SAGE Awards and will be looking for entries that show innovation in the field of GI care and a significant improvement in patient care. The judging panel's assessment of entries, selection of evaluation criteria, meetings, deliberations and decisions are entirely independent of Shire.
BSG - BASL Decompensated Cirrhosis Care Bundle - First 24 Hours
Friday, 05 December 2014 10:30
Decompensated cirrhosis is a medical emergency with a high mortality. Effective early interventions can save lives and reduce hospital stay. This checklist should be completed for all patients admitted with decompensated cirrhosis within the first 6 hours of admission.
The recent NCEPOD report 2013 on alcohol related liver disease highlighted that the management of some patients admitted with decompensated cirrhosis in the UK was suboptimal. Admission with decompensated cirrhosis is a common medical presentation and carries a high mortality (10-20% in hospital mortality).
Early intervention with evidence-based treatments for patients with the complications of cirrhosis can save lives. This checklist aims to provide a guide to help ensure that the necessary early investigations are completed in a timely manner and appropriate treatments are given at the earliest opportunity.
Page 1 of 3